SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April, 2007

 

SkyePharma PLC

---

(Translation of registrant's name into English)

 

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

---

 

                     CIRCULAR POSTED TODAY TO SHAREHOLDERS


LONDON, UK, APRIL 18, 2007-- SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) announces
that a Circular containing details of  a new long-term incentive plan (the
"LTIP") will today be posted to shareholders.

The Circular includes a notice convening an Extraordinary General Meeting to be
held at 11.00 a.m. on 4 May 2007 at the offices of Fasken Martineau Stringer
Saul LLP, 4th Floor, 17 Hanover Square, London, W1S 1HU at which a resolution
will be proposed to approve the LTIP.


For further information please contact:

SkyePharma PLC                                                  +44 207 491 1777

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director

Financial Dynamics                                             +44 207 7831 3113

David Yates
Deborah Scott

The Trout Group                                                 + 1 617 583 1308

Seth Lewis


About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Company has nine approved products in the areas of oral,
inhalation and topical delivery that are marketed throughout the world by
leading pharmaceutical companies. For more information, visit

www.skyepharma.com.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ John Murphy

                                                                       Name: John Murphy
                                                                          Title: Company Secretary

Date:   April 18, 2007